The overall objective of the Clinical Core is to recruit, evaluate and follow patients with Alzheimer's disease (AD), related dementing disorders and normal controls to provide well-characterized subjects for clinical research projects and subsequent pathologic studies.
The specific aims are a) to recruit, evaluate and systematically longitudinally follow patients with AD and related dementing disorders, b) to recruit and evaluate a series of cognitively normal community-dwelling (N=400) or nursing home (N=50) volunteer control subjects who have consented to prearranged autopsy, c) to provide a systematic longitudinal follow-up of cognitive function (annual) and neurologic findings (every other year) of control subject, d) to maintain a clinical, neuropsychologic and behavioral database on AD, related dementing disorders, and control subjects, e) to increase the number of AD patients who come to autopsy and then investigate associations between neurologic, neuropsychologic, and behavioral findings as they relate to quantitative histopathologic and regional changes found at autopsy, f) to continue participation in multicenter therapeutic drug trial, g) to continue participation in consortium projects including the AD Cooperative Studies and CERAD, h) to increase the number of AD and related disorders patients (minority and rural) in our Satellite Diagnostic and Treatment Clinics, and i) to enroll minority and rural control subjects through our Satellite Diagnostic and Treatment Clinics. We presently follow 500 patients in our Memory Disorders Clinic. We have recruited 317 cognitively normal volunteer control subjects, all of whom have consented to brain donation at death.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005144-13
Application #
5204501
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
13
Fiscal Year
1996
Total Cost
Indirect Cost
Broster, Lucas S; Li, Juan; Wagner, Benjamin et al. (2018) Spared behavioral repetition effects in Alzheimer's disease linked to an altered neural mechanism at posterior cortex. J Clin Exp Neuropsychol 40:761-776
Petyuk, Vladislav A; Chang, Rui; Ramirez-Restrepo, Manuel et al. (2018) The human brainome: network analysis identifies HSPA2 as a novel Alzheimer’s disease target. Brain 141:2721-2739
Sims, Rebecca (see original citation for additional authors) (2017) Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet 49:1373-1384
Reed, Rebecca G; Greenberg, Richard N; Segerstrom, Suzanne C (2017) Cytomegalovirus serostatus, inflammation, and antibody response to influenza vaccination in older adults: The moderating effect of beta blockade. Brain Behav Immun 61:14-20
Li, Juan; Broster, Lucas S; Jicha, Gregory A et al. (2017) A cognitive electrophysiological signature differentiates amnestic mild cognitive impairment from normal aging. Alzheimers Res Ther 9:3
Karch, Celeste M; Ezerskiy, Lubov A; Bertelsen, Sarah et al. (2016) Alzheimer's Disease Risk Polymorphisms Regulate Gene Expression in the ZCWPW1 and the CELF1 Loci. PLoS One 11:e0148717
Mez, Jesse; Mukherjee, Shubhabrata; Thornton, Timothy et al. (2016) The executive prominent/memory prominent spectrum in Alzheimer's disease is highly heritable. Neurobiol Aging 41:115-121
Ridge, Perry G; Hoyt, Kaitlyn B; Boehme, Kevin et al. (2016) Assessment of the genetic variance of late-onset Alzheimer's disease. Neurobiol Aging 41:200.e13-200.e20
Hohman, Timothy J; Bush, William S; Jiang, Lan et al. (2016) Discovery of gene-gene interactions across multiple independent data sets of late onset Alzheimer disease from the Alzheimer Disease Genetics Consortium. Neurobiol Aging 38:141-150
Wei, Shaoceng; Kryscio, Richard J (2016) Semi-Markov models for interval censored transient cognitive states with back transitions and a competing risk. Stat Methods Med Res 25:2909-2924

Showing the most recent 10 out of 236 publications